Peer-influenced content. Sources you trust. No registration required. This is HCN.

How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population

In the past decade, several promising immunotherapies have been developed, changing the treatment landscape for children with relapsed acute lymphoblastic leukemia (ALL). These advances in treatment offer real promise for less toxic and more effective therapy for children. In this article from Blood, the authors present several cases highlighting contemporary treatment decision-making.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form